BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    

NorthStar Biotech Launches $20 Million Private Placement Round With Proceeds to Fund Bioheart, Inc. Trials

10/15/2012 7:29:47 AM

SUNRISE, FL--(Marketwire - October 15, 2012) - NorthStar Biotech, LLC, a consortium of Bioheart, Inc. (OTCQB: BHRT) Directors and Shareholders, led by Managing Director Chuck Hart, has launched a series A private placement financing round and intends to raise a maximum capital of $20 million in exchange for 30% of the company.

"With the intellectual property of Bioheart, NorthStar Biotech is well positioned to become a leader in the field of cardiology. We are also pursuing several opportunities which will make it a leader in regenerative medicine," said Chuck Hart, Managing Director of NorthStar Biotech LLC and a Bioheart Director and longtime shareholder.

Bioheart had previously announced the formation of NorthStar Biotech in August of 2012, a consortium formed by major shareholders and insiders to purchase and protect Bioheart's senior debt that was collateralized with its intellectual property and technology. The primary use of the proceeds raised by the private placement is to fund Bioheart efforts including the Phase II/III MARVEL trial with muscle stem cells, the Phase I REGEN trial with gene modified muscle stem cells and the ANGEL trial with adipose derived stem cells.

Bioheart's cell therapy products address an unmet need in the cardiac market by providing true regenerative medicine where the MyoCell® product line may regenerate muscle in areas of scar tissue and the LipiCell® product may help reduce inflammation and promote the growth of new blood vessels.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About NorthStar Biotech, LLC

NorthStar Biotech was founded in 2012 and is focused on the development of regenerative medicine for a variety of degenerative diseases. It maintains an exclusive, international license to the products and intellectual property rights of Bioheart, Inc. ("Bioheart"). NorthStar is currently raising sums to complete clinical testing required by Bioheart; to create and oversee an international sales force for Bioheart; and to sell and distribute the Bioheart products and Bioheart IP on an international basis.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2012.

Media Contact:
Rhonda Madaris
13794 NW 4th Street
Suite 212
Sunrise, FL 33325
Telephone 954/835-1500

Read at